Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002147 · ClinicalTrials.gov registry record · Phase 3
Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
A Phase 3 study, sponsored by Sequus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002147: Completed Phase 3 study, sponsored by Sequus Pharmaceuticals.
NCT00002147 is a Phase 3 study that has completed, run by Sequus Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002147, a Phase 3 study, has completed, sponsored by Sequus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's sarcoma patients who have no remaining treatment options other than DOX-SL or patients who have been participating in another DOX-SL protocol and for whom continuation in DOX-SL is medically indicated. Also, to evaluate the safety and efficacy of DOX-SL in patients with Kaposi's sarcoma who have previously received systemic chemotherapy with or without an anthracycline.
Interventions
- DRUG Doxorubicin hydrochloride (liposomal)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00002147 record still lists
NCT00002147 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Doxorubicin hydrochloride (liposomal) is the first listed.
NCT00002147 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002147 about?
NCT00002147 is a clinical study titled "Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.". To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's sarcoma patients who have no remaining treatment options other than DOX-SL or patients who have been participating in another DOX-SL protocol and for whom continuation in DOX-SL is medically indicated. Also, ...
What is the current status of trial NCT00002147?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002147?
The interventions under investigation include: Doxorubicin hydrochloride (liposomal) (DRUG).
Who is sponsoring clinical trial NCT00002147?
This trial is sponsored by Sequus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.